Valeant Pharmaceuticals International, Inc. announced it has paid down an additional $300 million of its senior secured term loans, using cash on hand. In aggregate, Valeant has now reduced its debt by more than $6.5 billion since the end of the first quarter of 2016. As of Dec. 31, 2017, the Company's total debt is approximately $25.7 billion.